Patents by Inventor Christopher Roy Bishop

Christopher Roy Bishop has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combination serotonin specific reuptake inhibitor and serotonin 1A receptor partial agonist for reducing L-DOPA-induced dyskinesia
    Patent number: 12285426
    Abstract: A method of treating and attenuating L-DOPA-induced dyskinesia, comprising administering an effective dose of at least one pharmacological agent, e.g., vilazodone, having serotonin-specific reuptake inhibition (SSRI) and serotonin receptor 1A (5-HT1AR) partial agonism activity, in conjunction with L-DOPA. Other agents, such as an L-DOPA decarboxylase inhibitor, e.g., carbidopa, or other adjunct treatments may also be provided.
    Type: Grant
    Filed: April 26, 2021
    Date of Patent: April 29, 2025
    Assignees: The Research Foundation for The State University of New York, Rosalind Franklin University of Medicine and Science, Board of Trustees of Michigan State University
    Inventors: Christopher Roy Bishop, Anthony West, Fredric Manfredsson
  • COMBINATION SEROTONIN SPECIFIC REUPTAKE INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST FOR REDUCING L-DOPA-INDUCED DYSKINESIA
    Publication number: 20210393621
    Abstract: A method of treating and attenuating L-DOPA-induced dyskinesia, comprising administering an effective dose of at least one pharmacological agent, e.g., vilazodone, having serotonin-specific reuptake inhibition (SSRI) and serotonin receptor 1A (5-HT1AR) partial agonism activity, in conjunction with L-DOPA. Other agents, such as an L-DOPA decarboxylase inhibitor, e.g., carbidopa, or other adjunct treatments may also be provided.
    Type: Application
    Filed: October 25, 2019
    Publication date: December 23, 2021
    Inventors: Christopher Roy Bishop, Anthony West, Fredric Manfresson
  • COMBINATION SEROTONIN SPECIFIC REUPTAKE INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST FOR REDUCING L-DOPA-INDUCED DYSKINESIA
    Publication number: 20210346372
    Abstract: A method of treating and attenuating L-DOPA-induced dyskinesia, comprising administering an effective dose of at least one pharmacological agent, e.g., vilazodone, having serotonin-specific reuptake inhibition (SSRI) and serotonin receptor 1A (5-HT1AR) partial agonism activity, in conjunction with L-DOPA. Other agents, such as an L-DOPA decarboxylase inhibitor, e.g., carbidopa, or other adjunct treatments may also be provided.
    Type: Application
    Filed: April 26, 2021
    Publication date: November 11, 2021
    Inventors: Christopher Roy Bishop, Anthony West, Fredric Manfresson